# CONTRA FUSION PHARMACE EQUITY

CONTRA FUSION PHARMACE EQUITY is a security (CUSIP 361CVR012) tracked across SEC portfolio filings. 2 institutional managers reported positions on Form 13F as of 2026-06-30; 4 registered fund positions totaling $30K via N-PORT as of 2026-03-31.

## Summary

- Issuer: CONTRA FUSION PHARMACE
- Class: EQUITY
- CUSIP: 361CVR012
- Asset category: DE
- 13F holders: 2
- 13F period: 2026-06-30
- N-PORT fund positions: 4
- N-PORT value: $30K
- N-PORT report: 2026-03-31

## Top institutional holders (Form 13F)

| Manager | Location | Value | Shares |
| --- | --- | --- | --- |
| [Skaana Management L.P.](https://search.stillhousedata.com/firm/311817) | BROOKLYN, NY | — | 50,000 |
| [GAMMA Investing LLC](https://search.stillhousedata.com/firm/312573) | FOSTER CITY, CA | — | 14 |

## Top fund holders (N-PORT)

| Fund | Registrant | Value | % of fund |
| --- | --- | --- | --- |
| abrdn Healthcare Investors | abrdn Healthcare Investors | $10K | 0.09% |
| abrdn Healthcare Opportunities Fund | abrdn Healthcare Opportunities Fund | $10K | 0.14% |
| abrdn World Healthcare Fund | abrdn World Healthcare Fund | $5K | 0.11% |
| abrdn Life Sciences Investors | abrdn Life Sciences Investors | $4K | 0.08% |

## More

- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/security/361CVR012.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.